Notification That Annual Report Will Be Submitted Late (nt 10-k)
01 Diciembre 2015 - 5:06AM
Edgar (US Regulatory)
| OMB APPROVAL |
| OMB Number: 3235-0058 |
| Expires: August 31, 2015 |
Estimated average burden
hours per response. . .2.50 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE
FILING
(Check One): [ ]Form 10-K [X] Form 20-F [ ]Form
11-K [ ]Form 10-Q [ ]Form N-SAR [ ]Form
N-CSR
For Period Ended: _August 31, 2015______________
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________
| Read Instruction (on back page) Before Preparing Form. Please Print or Type. |
| Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
If the notification relates to a portion of
the filing checked above, identify the Item(s) to which the notification relates:
_________________________________________________________________________________
| PART I -- REGISTRANT INFORMATION |
|
Oncologix Tech, Inc.
______________________________________
Full Name of Registrant |
|
BestNet Communications Corp. and Wavetech International,
Inc.________________________________
Former Name if Applicable |
|
1604 W. Pinhook Rd. #200 ______________________________________________________
Address of Principal Executive Office (Street and Number) |
|
Lafayette, LA 70508__________________________________________
City, State and Zip Code |
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check
box if appropriate)
| [X] |
(a) The reasons described in reasonable detail
in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III -- NARRATIVE
State below in reasonable
detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed
within the prescribed time period.
Oncologix Tech, Inc.
(the “Company”) could not complete the filing of its Annual Report on Form 10-K for the twelve months ended August
31, 2015 due to the Company’s recent acquisition of Esteemcare Inc. and Affordable Medical Equipment Solutions Inc.. The
Company, its independent EDGAR firm needed additional time to complete the review and processing of the 10K. In accordance with
Rule 12b-25 of the Securities Exchange Act of 1934, the Company will file its Form 10-Q no later than the fifthteenth calendar
day following the prescribed due date.
(Attach Extra Sheets if Needed)
PART IV-- OTHER INFORMATION
(1) Name and telephone number of person to
contact in regard to this notification
| |
Michael A. Kramarz_______
(Name) |
(616)______
(Area Code) |
977-9933_________________
(Telephone Number) |
(2) Have all other periodic
reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for
such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). [X]Yes
[ ]No
(3) Is it anticipated
that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or portion thereof?[ ]Yes
[X]No
If so, attach an explanation
of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Oncologix
Tech Inc.________
(Name of Registrant as Specified in Charter)
has caused this notification
to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 30,
2015_______ By: /s/Michael A. Kramarz________________
Michael A. Kramarz,
Chief Financial Officer
INSTRUCTION: The form
may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant
by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf
of the registrant shall be filed with the form.
ATTENTION
| Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
General Instructions
| 1. | This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under
the Securities Exchange Act of 1934. |
| 2. | One signed original and four conformed copies of this form and amendments thereto must be completed
and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules
and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the
Commission files. |
| 3. | A manually signed copy of the form and amendments thereto shall be filed with each national securities
exchange on which any class of securities of the registrant is registered. |
| 4. | Amendments to the notifications must also be filed on Form 12b-25 but need not restate information
that has been correctly furnished. The form shall be clearly identified as an amended notification. |
| 5. | Electronic filers. This form shall not be used by electronic filers unable to timely file
a report solely due to electronic difficulties. Filers unable to submit a report within the time period prescribed due to difficulties
in electronic filing should comply with either Rule 201
or Rule 202 of Regulation S-T (§232.201 or
§232.202 of this chapter) or apply for an adjustment in filing date pursuant to Rule 13(b) of Regulation S-T (§232.13(b)
of this Chapter). |
| 6. | Interactive date submissions. This form shall not be used by electronic filers with respect to
the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post
an Interactive Data File within the time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201
or §232.202 of this chapter). |
Oncologix Tech (CE) (USOTC:OCLG)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Oncologix Tech (CE) (USOTC:OCLG)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
